Talecris Biotherapeutics Announces Results of Annual Stockholders' Meeting
Published: May 03, 2011
RESEARCH TRIANGLE PARK, N.C., May 3, 2011 /PRNewswire/ -- Talecris Biotherapeutics Holdings Corp. (NASDAQ: TLCR) held its annual meeting of stockholders today in Chapel Hill, N.C., where four proposals were submitted to, and approved by, stockholders.
Stockholders elected three directors to the company's Board of Directors to hold office for a three-year term until the annual meeting of stockholders in 2014, and until their successors are elected and qualified. The three directors are W. Brett Ingersoll, Lawrence D. Stern and Ruedi E. Waeger, PhD.
Stockholders also ratified the appointment of PricewaterhouseCoopers LLP as the company's independent, registered, public accounting firm for the fiscal year ending December 31, 2011.
In a pair of advisory and non-binding votes, stockholders approved the compensation of the company's named executive officers and recommended holding an advisory vote every three years on compensation of the company's named executive officers.
A replay of the meeting will be available beginning at 1 p.m. EDT and will remain accessible until May 10, 2011, by dialing 1-888-286-8010 (domestic) or 1-617-801-6888 (international). The pass code is 86974301. The webcast of the meeting call will be archived on the Investor Relations section of http://www.talecris.com.
About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.
Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, neurology and hemostasis. For more information, please visit: www.talecris.com.
SOURCE Talecris Biotherapeutics Holdings Corp.